Event: Solutions for Drug-Resistant Infections conference
The Solutions for Drug-Resistant Infections 2017 conference will bring together leading scientific, medical and industry experts to discuss new solutions and an integrated ‘one health’ approach to the global challenge of drug-resistant pathogens.
The conference will take place at the Brisbane Convention and Exhibition Centre in Australia from 3 - 5 April 2017.
New drugs for drug-resistant infections
Who should attend?
This conference will provide a forum for senior research leaders and key industry representatives working in the fields of microbiology, virology, parasitology, genomics, pharmacology and medicinal chemistry to network and discuss new ways to solve the global challenge of drug-resistant infections in human and animal health.
Our goal for SDRI 2017 is to lead a concerted discussion to set three priorities and guide research efforts towards global solutions for drug resistance research.
Conference session highlights
- Antimicrobial drug discovery
- Improvements to existing anti-infective agents and repurposing
- New drug targets
- Alternate therapies
- Navigating the pipeline
- International models and funding
- Vector control and vaccines
Plenary and keynote speakers
- Professor Dame Sally Davies DBE FMedSci FRS, Chief Medical Officer for England
- Professor Ramanan Laxminarayan, Public Health Foundation of India
- Professor John Rex, Chief Strategy Officer, CARB-X; and Voting Member, US PACCARB
- Mr Jason Gale, Senior Editor, Bloomberg News
- A/Professor Scott Beatson, The University of Queensland
- Dr Qin Cheng, Australian Army Malaria Institute
- A/Professor Heidi Drummer, Burnet Institute
- Professor Ian Gilbert, Drug Discovery Unit, University of Dundee
- Professor Bob Hancock, University of British Columbia
- Dr Timothy Jinks, Strategy Development Lead, Wellcome Trust
- Professor Anne Kelso, National Health and medical Research Council (NHMRC)
- Dr Jennifer Leeds, Head of Antibacterial Discovery, Novartis
- Dr Didier Leroy, Medicines for Malaria Venture (MMV)
- Dr Line Matthiessen-Guyader, Head of Unit, Research Directorate-General, Biotechnology, Agriculture and Food Research, European Commission
- Dr Alita Miller, Entasis Therapeutics
- Dr Jean-Pierre Paccaud, DNDi
- Dr Nicole Petter, University of Technology Sydney
- Dr Kade Roberts, Monash University
- Dr Terry Roemer, Head of Antimicrobial Discovery, Merck, USA
- A/Professor Gilda Tachedjian, Burnet Institute
- Professor Man-Wah Tam, Director, Infectious Disease, Genentech
- Professor Subhash Vasuveban, Duke-NUS Graduate Medical School
- Dr Tony Velkov, Monash University
- Professor Elizabeth Winzeler, University of California
- Professor Gerry Wright, Michael G. DeGroote Institute for Infectious Disease Research, UK
- Dr Michelle Wykes, QIMR Berghofer Medical Research Institute
- Dr Zuoyu Xu, National Institute of Allergy and Infectious Diseases
- Professor Helen Zgurskaya, University of Oklahoma
The SDRI scientific committee welcomes your abstract submission for inclusion in the 2017 program.
Submissions for poster presentations must be received by 17 February 2017.
Why SDRI 2017?
By 2050, it is estimated that nearly 10 million annual deaths globally will be attributable to bacterial antimicrobial resistance alone (Source: Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations, 2014).
Globally, incidences of drug resistance in bacterial infections, dengue, tuberculosis and malaria continue to rise. Diseases caused by these pathogens are becoming more deadly and difficult to treat. New therapies are urgently needed to prevent a return to the preantibiotic era, when even simple infections caused death.